Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer's-related psychosis during the ...

Since its approval in 2023, the Alzheimer's disease drug made by Biogen Inc. and Eisai has seen a lackluster launch. However, Biogen CEO Chris Viehbacher said on Tuesday that there are a “number of ...

FDA sets August 31, 2025, as the action date for Eisai and Biogen's Leqembi subcutaneous autoinjector ... patients with Mild ...

A report questions the FDA's accelerated approval process citing Sarepta and Biogen therapies as examples. Read more here.

Biogen CEO Chris Viehbacher targets subcutaneous Leqembi release for Alzheimers treatment Biogens Chris Viehbacher outlines ...

GlobalData analysts are predicting an Alzheimer’s disease market boom, tipping its value across major regions to increase ...

Biogen (BIIB) and Eisai's (ESALF) (ESAIY) announce that U.S. FDA agreed to review their subcutaneous form of Alzheimer's ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for Alzheimer’s disease in 2025. Companies including Biogen Inc. and Eli ...

Biogen and Eisai have announced that the US Food and Drug Administration (FDA) has accepted a Biologics License Application ...

On Monday, the FDA accepted Eisai Co., Ltd. (OTC:ESALY) and Biogen Inc’s (NASDAQ ... Cognitive Impairment or mild dementia stage of the disease. A Prescription Drug User Fee Act (PDUFA) action ...